Laboratory Incidents and Validation Fail
In November 2025, the USFDA issued a Warning Letter to Bangalore-based Cdymax India following an
Discussion forum for Pharma Quality events, Regulatory Actions
Warning letters, 483s, Recalls, Import Alerts, Audit observations
